Any current/future new fundraising through debt or equity?

No explicit mention of any current or future fundraising plans through debt or equity in the transcript. The company has repaid external loans using IPO proceeds and currently has gross debt of around INR 250 crores, including internal debt from the parent. Management indicated that the IPO proceeds have been mostly utilized as per plans, with no deviations. Interest costs are expected to reduce in Q4 as existing loans are repaid. The company is actively looking for acquisitions but has not closed any deals yet. No specific plans disclosed for raising fresh funds through debt or equity at this

Any current/future capex/capital investment/strategic investment?

A new facility has been identified in Mysore to support growth in the medical and industrial sectors; it is a leased premise in a software park being converted for this purpose, expected ready next financial year. The anticipated capex on the Mysore plant is minimal, approximately a couple of million dollars. A new precision machining facility was inaugurated in Bangalore, providing 36,000 sq ft of manufacturing capability, focusing on high-value, vertically integrated services. Supply chain optimization is underway with a focus on automation, supported by new leadership hires to strengt

Future growth expectations in sales/revenue/volumes?

The company expects healthy growth in revenue supported by a robust and "sufficiently large" pipeline of orders. Current order book visibility extends 12 to 18 months, with some orders executable over three years. Management is confident about maintaining an order book around INR 2,000 crores for upcoming quarters. The business is focused on converting a strong pipeline into orders, with a solid track record of doing so. They anticipate growth not only from existing clients by increasing wallet share but also from new client additions. Investments in leadership and capacity expansions (e.g., n

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue for Q3 FY24 grew by 49.7% YoY; nine-month revenue growth is 49.6%, indicating strong top-line momentum. EBITDA margin for Q3 is 9.2%, slightly down due to planned SG&A investments aimed at scaling the business. Management expects EBITDA margin to reach around 10%-10.5% in Q4 and inch further towards 11%-12% as scale benefits and mix improvement happen. Profit after tax surged 222.6% YoY in Q3, boosted by other income and volume growth; nine-month profits doubled. SG&A investments, including leadership additions and RSU costs, lead to near-term margin pressure but are positioned for med

Current/ Expected Orderbook/ Pending Orders?

The current order book stands around INR2,294 crores, and it has been largely stable or slightly flat over recent quarters, with some lumpiness due to large strategic program timings. The typical order execution period ranges roughly between 12 to 18 months, although some orders can extend up to 24-30 months depending on the industry. Despite a flat order book trend recently, management expresses confidence in a healthy and considerable pipeline of orders which they expect to convert into business in the coming quarters, potentially leading to order book growth. Recent disclosures indica

Cyient DLM LtdQ4 FY24

Cyient DLM Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹697P/E: 64.3Market Cap: ₹5.3K Cr

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→The company expects healthy growth in revenue supported by a robust and "sufficiently large" pipeline of orders.
→Current order book visibility extends 12 to 18 months, with some orders executable over three years.
→Management is confident about maintaining an order book around INR 2,000 crores for upcoming quarters.
→The business is focused on converting a strong pipeline into orders, with a solid track record of doing so.
→They anticipate growth not only from existing clients by increasing wallet share but also from new client additions.
→Investments in leadership and capacity expansions (e.g., new facilities in Mysore and Bangalore) support growth in medical, industrial, aerospace, and defense sectors.
→SG&A investments have peaked, with expectations to reach and sustain double-digit EBITDA margins as revenue grows.
→Overall, positive outlook for FY25 growth with guidance to be provided in Q4 results.

Margin guidance

Category 2

→Revenue for Q3 FY24 grew by 49.7% YoY; nine-month revenue growth is 49.6%, indicating strong top-line momentum.
→EBITDA margin for Q3 is 9.2%, slightly down due to planned SG&A investments aimed at scaling the business.
→Management expects EBITDA margin to reach around 10%-10.5% in Q4 and inch further towards 11%-12% as scale benefits and mix improvement happen.
→Profit after tax surged 222.6% YoY in Q3, boosted by other income and volume growth; nine-month profits doubled.
→SG&A investments, including leadership additions and RSU costs, lead to near-term margin pressure but are positioned for medium-to-long-term growth towards $300-500 million revenue.
→Order book remains strong and is sufficient for healthy growth in FY25 and beyond, supporting sustained revenue and profit growth.
→Free cash flow expected to turn positive in Q4, enhancing financial health.
→Overall, consistent growth trajectory with improving operating leverage expected over coming quarters.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of any current or future fundraising plans through debt or equity in the transcript.
→The company has repaid external loans using IPO proceeds and currently has gross debt of around INR 250 crores, including internal debt from the parent.
→Management indicated that the IPO proceeds have been mostly utilized as per plans, with no deviations.
→Interest costs are expected to reduce in Q4 as existing loans are repaid.
→The company is actively looking for acquisitions but has not closed any deals yet.
→No specific plans disclosed for raising fresh funds through debt or equity at this time.

Order book

→The current order book stands around INR2,294 crores, and it has been largely stable or slightly flat over recent quarters, with some lumpiness due to large strategic program timings.
→The typical order execution period ranges roughly between 12 to 18 months, although some orders can extend up to 24-30 months depending on the industry.
→Despite a flat order book trend recently, management expresses confidence in a healthy and considerable pipeline of orders which they expect to convert into business in the coming quarters, potentially leading to order book growth.
→Recent disclosures indicate advanced discussions and potential deal closures, including several large deals and two new client additions in aerospace and defense sectors.
→The company aims to maintain the current order book level (~INR2,000 crores+) with confidence, driven by consistent end market demand and an active pipeline.
→Management plans to provide more detailed industry-wise order book breakup in future disclosures.

Capex plans

Yes

→A new facility has been identified in Mysore to support growth in the medical and industrial sectors; it is a leased premise in a software park being converted for this purpose, expected ready next financial year.
→The anticipated capex on the Mysore plant is minimal, approximately a couple of million dollars.
→A new precision machining facility was inaugurated in Bangalore, providing 36,000 sq ft of manufacturing capability, focusing on high-value, vertically integrated services.
→Supply chain optimization is underway with a focus on automation, supported by new leadership hires to strengthen capabilities.
→No significant additional SG&A or capital investments are currently expected beyond these plans, as stated by management.
→Discussions indicate ongoing capacity utilization optimization, with Mysore near peak and Hyderabad with lower utilization but expected to support future growth.

How does Cyient DLM Ltd rank vs peers in ?

Pro feature

1Cyient DLM Ltd

Rev 2Mar 2

See full sector rankings

Want more stocks like Cyient DLM Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio